Oral fecal transplantation enriches Lachnospiraceae and butyrate to mitigate acute liver injury

Cell Rep. 2024 Jan 23;43(1):113591. doi: 10.1016/j.celrep.2023.113591. Epub 2023 Dec 27.

Abstract

While fecal microbiota transplantation (FMT) shows promise in treating human diseases, oral capsule FMT is more accepted and accessible to patients. However, microbe selection in the upper gastrointestinal tract (UGIT) through oral administration remains unclear. Here, we demonstrate that short-term oral fecal gavage (OFG) alleviates acetaminophen-induced acute liver injury (AILI) in mice, regardless of the divergent effects of commensal gut microbes. Pasteurized fecal gavage yields similar therapeutic effects. OFG enriches gut Lachnospiraceae and butyrate compared to donor feces. Butyrate mitigates AILI-induced ferroptosis via AMPK-ULK1-p62 signaling to simultaneously induce mitophagy and Nrf2 antioxidant responses. Combined N-acetylcysteine and butyrate administration significantly improves AILI mouse survival rates. These observations indicate the significance of the UGIT in modulating the implanted fecal microbes through oral administration and its potential biological and clinical impacts. Our findings also highlight a possible strategy for applying microbial metabolites to treat acute liver injury.

Keywords: CP: Cell biology; CP: Microbiology; DILI; FMT; Nrf2; acetaminophen; acute liver failure; drug-induced liver injury; fecal microbiota transplantation; ferroptosis; gut-liver axis; short-chain fatty acids.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Butyrates*
  • Fecal Microbiota Transplantation*
  • Feces
  • Humans
  • Liver
  • Mice

Substances

  • Butyrates